- Home
- HIT vs LUNG Comparison
HIT vs LUNG Comparison
Compare HIT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIT | LUNG |
|---|---|---|
| Founded | 1964 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 72.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HIT | LUNG |
|---|---|---|
| Price | $1.78 | $1.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $2.50 | ★ $5.38 |
| AVG Volume (30 Days) | 264.1K | ★ 680.2K |
| Earning Date | 04-13-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | $67.75 | $6.20 |
| Revenue Next Year | $29.85 | $21.61 |
| P/E Ratio | $52.01 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.51 | $1.31 |
| 52 Week High | $4.01 | $7.97 |
Technical Indicators
Market Signals| Indicator | HIT | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 37.62 |
| Support Level | $1.09 | N/A |
| Resistance Level | $2.08 | $2.01 |
| Average True Range (ATR) | 0.24 | 0.17 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 70.00 | 5.29 |
Price Performance
Historical ComparisonAbout HIT Health In Tech Inc.
Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.